ArticleFrontiers in cardiovascular medicine2025
Prognostic implications of right ventricular to pulmonary artery uncoupling in cardiac amyloidosis.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Right ventricular-pulmonary arterial (RV-PA) uncoupling in cardiac amyloidosis (CA) has been underexplored, with focus mainly on tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP). This study aims to evaluate the association of various echocardiographic surrogates of RV-PA coupling with outcomes in cardiac transthyretin (ATTR-CA) and light-chain (AL-CA) amyloidosis. Methods: We analyzed RV-PA coupling in patients diagnosed with ATTR-CA and AL-CA at our center between 2014 and 2023. RV-PA coupling was assessed using TAPSE/PASP, fractional area change (FAC)/PASP, and RV free wall strain (RVFWS)/PASP. The primary endpoint was all-cause mortality. Results: A total of 120 patients (86% ATTR-CA, 14% AL-CA) were included in the study (median age 77 years, 88% male). During a median follow-up period of 23 (IQR: 15-34) months, the primary endpoint occurred in 25 patients (21%). The study population was stratified based on the ROC-derived TAPSE/PASP cutoff of <0.30 mm/mmHg, demonstrating RV-PA uncoupling. Lower RV-PA coupling surrogates were independently associated with higher mortality (HR per +0.1 unit: TAPSE/PASP, 0.74, 95% CI: 0.59-0.93, Conclusions: RV-PA uncoupling may be linked to a higher risk of all-cause mortality in CA. TAPSE/PASP outperformed numerically FAC/PASP and RVFWS/PASP in predicting long-term survival, although it did not clearly outperform established RV function parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.